Sign In
Buy PTCT
$68.68
+0.450 (+0.660%)
At Close: Jun 03, 2026
PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2024 Financial Results
07:00am, Thursday, 24'th Oct 2024
WARREN, N.J., Oct. 24, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its third quarter 2024 financial resul
CHMP Maintains Negative Opinion on Translarna™ Reexamination
06:30am, Friday, 18'th Oct 2024
- Opinion to be reviewed by European Commission - WARREN, N.J. , Oct. 18, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the Committee for Medicinal Products for Human
Will PTC Therapeutics (PTCT) Report Negative Q3 Earnings? What You Should Know
11:05am, Thursday, 17'th Oct 2024
PTC Therapeutics (PTCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PTC Therapeutics Announces FDA Target Regulatory Action Date for Sepiapterin and Lancet Publication of Phase 3 Trial Results
04:30pm, Monday, 14'th Oct 2024
WARREN, N.J. , Oct. 14, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the FDA has set a target regulatory action date of July 29, 2025, for the review of the New D
PTC Therapeutics (PTCT) Surges 16.5%: Is This an Indication of Further Gains?
04:10pm, Wednesday, 09'th Oct 2024
PTC Therapeutics (PTCT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength dow
PTCT Stock Rises on Positive Updates on Friedreich Ataxia Program
02:40pm, Wednesday, 09'th Oct 2024
PTC Therapeutics announces positive results from long-term treatment studies on vatiquinone for the treatment of Friedreich ataxia.
- Statistically significant results on primary endpoint of long-term study analyses - - Following FDA pre-NDA feedback, submission on track for December 2024 - WARREN, N.J. , Oct. 8, 2024 /PRNewswire/
3 Top Stocks That Could Still Rocket Higher in 2024
05:17am, Friday, 04'th Oct 2024
Upcoming Food and Drug Administration decisions could push these stocks through the roof.
WARREN, N.J. , Oct. 1, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the FDA has accepted for filing the New Drug Application (NDA) of sepiapterin for the treatment of ped
FDA Grants Fast Track Designation to PTC518 Huntington's Disease Program
08:00am, Thursday, 26'th Sep 2024
WARREN, N.J. , Sept. 26, 2024 /PRNewswire/ -- PTC Therapeutics (NASDAQ: PTCT) announced today that the FDA has granted Fast Track designation to the PTC518 program for the treatment of Huntington's di
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Thursday, 12'th Sep 2024
WARREN, N.J. , Sept. 12, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Sept.
PTC Therapeutics: Positive HD Data Along With NDA Submission Brings Further Value
04:13pm, Thursday, 12'th Sep 2024
PTC Therapeutics, Inc. achieved dose-dependent lowering of mutant Huntingtin protein in both the blood and CSF of HD patients, using 5 mg and 10 mg of PTC518. The global Huntington's Disease treatment
PTC Therapeutics to Participate at Upcoming Investor Conferences
04:30pm, Wednesday, 28'th Aug 2024
WARREN, N.J. , Aug. 28, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the following conferences: Morgan Stanley 22nd A
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
10:00am, Sunday, 11'th Aug 2024
NEW YORK, NY / ACCESSWIRE / August 11, 2024 / Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ:PTCT). Such investors are advised
PTC Therapeutics, Inc. (PTCT) Q2 2024 Earnings Call Transcript
11:53am, Friday, 09'th Aug 2024
PTC Therapeutics, Inc. (NASDAQ:PTCT ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Ron Aldridge – Senior Director of Investor Relations Matthew Klein - Chief Execu
